Literature DB >> 27919595

The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study.

Mohammad Zandi1, Arash Dehghan2, Pejman Janbaz3, Hamid Malekzadeh4, Payam Amini5.   

Abstract

OBJECTIVE: Although over a decade has passed since first introduction of BRONJ, the exact pathophysiology of this disease is still unclear. The present experimental study aimed to determine whether the oral mucosa or alveolar bone serves as the starting point for BRONJ development. SUBJECTS AND METHODS: Sixty male Wistar rats were randomly assigned into study and control groups (each, n = 30), and received intraperitoneal injection of 0.06 mg/kg zoledronate and saline, respectively, once a week for 12 weeks. At the end of the week 4 of the experiment, all 60 rats underwent unilateral mandibular first molar extraction. A 4 mm defect was made in the contralateral canine alveolar mucosa. At the end of the experiment, rats were sacrificed, and the three areas of interest including extraction, soft tissue defect, and the non-intervention (canine area on the same side of extraction) sites were assessed clinically for presence of bone exposure/fistula, and histologically for status of bone remodeling (only at extraction site) and osteonecrosis.
RESULTS: In the study group, the frequency of bone exposure/fistula was 80%, 0%, and 0%; and the rate of histological bone necrosis was 83.3%, 20%, and 0%; at the extraction, soft tissue defect, and non-intervention sites, respectively. No clinical and histological sign of bone necrosis was found in the control group. Normal bone remodeling was observed in 0% and 100% of the extraction sockets in the study and control groups, respectively.
CONCLUSION: Injury to alveolar bone was a stronger trigger for BRONJ development compared to oral mucosal damages.
Copyright © 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal study; Bisphosphonate; Jaw; Osteonecrosis; Pathophysiology

Mesh:

Year:  2016        PMID: 27919595     DOI: 10.1016/j.jcms.2016.10.015

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.

Authors:  Mohammad Zandi; Arash Dehghan; Payam Amini; Shideh Doulati; Leila Rezaeian
Journal:  Clin Oral Investig       Date:  2019-02-04       Impact factor: 3.573

Review 3.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 5.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

6.  Can topical phenytoin combined with tetracycline enhance the healing process in medication-related osteonecrosis of jaw? A comparative study.

Authors:  Reza Tabrizi; Kazem Khiabani; Shervin Shafiei; Ghazal Nosrati; Hamidreza Moslemi
Journal:  Natl J Maxillofac Surg       Date:  2022-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.